Article Details
Retrieved on: 2025-03-08 07:05:07
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article details FDA approvals for lenalidomide and dasatinib, highlighting their adverse effects, including peripheral edema, particularly in hematologic conditions like multiple myeloma and chronic myelogenous leukemia. This correlates with the tags and key concept.
Article found on: www.cancernetwork.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here